Medication Quality & Certificate of Analysis
At Potere Health MD, we believe patients deserve clear information about the medication they are prescribed. When compounded GLP-1 medication is used, we review pharmacy documentation and provide lot-specific Certificate of Analysis information when available.
This page is designed to help patients understand what a COA shows, what it does not show, and how to compare the medication lot on their vial with the documentation provided.
LegitScript-Certified
LegitScript-certified for transparency, compliance, and patient confidence.
Lot-Specific Documentation
A Certificate of Analysis provides testing information for a specific medication lot.
Pharmacy Documentation
We request quality documentation from our pharmacy partners when available.
Transparent GLP-1 Care
We believe patients should have access to clear pricing, medication information, and physician guidance.
Current Tirzepatide Certificate of Analysis
Medication: Tirzepatide 20 mg/mL with glycine
Lot number: 080326-TIR-20-GLY
Pharmacy listed: Kaduceus Pharmacy
Report date: Aug 5, 2026
Date of analysis: Aug 3, 2026
Assay result: 99.6%
Result: Pass
Current Semaglutide Certificate of Analysis
Medication: Semaglutide 5 mg/mL with B12
Lot number: 080326-SEM-B12-5
Pharmacy listed: Kaduceus Pharmacy
Report date: Aug 5, 2026
Date of analysis: Aug 3, 2026
Assay result: 98.5%
Result: Pass
What Is a Certificate of Analysis for GLP-1 Medications?
A Certificate of Analysis, often called a COA, is a lot-specific testing document. For compounded GLP-1 medicatoins, a COA may include information such as medication identity, concentration, assay or potency, lot number, date of analysis, and pass/fail result.
A COA is one part of medication quality review. It helps document testing information for a specific medication lot, but it does not replace medical judgment, pharmacy standards, or individualized prescribing decisions.
Why Does Potere Health MD Share COA Information?
Potere Health MD shares Certificate of Analysis information because patients deserve transparency about the medication they are prescribed.
Many patients have questions about compounded GLP-1 medication. Sharing lot-specific documentation makes it easier to understand where medication information comes from, what testing has been reported, and what questions to ask before starting treatment.
How Do I Check the Lot Number on My Medication?
When you receive your medication, look at the label on your vial. The label should include details such as the medication name, concentration, pharmacy, and lot number.
You can compare the lot number on your vial with the Certificate of Analysis information shown on this page. If you have questions about your label, dose, concentration, or lot number, contact Potere Health MD before injecting the medication.
Are Compounded GLP-1 Medications FDA-Approved?
Compounded medications are not FDA-approved. This means they are not reviewed by FDA for safety, effectiveness, or quality before marketing.
A Certificate of Analysis is lot-specific testing documentation. It should not be interpreted as FDA approval or as proof that a compounded medication is identical to a brand-name medication.
At Potere Health MD, compounded medication is prescribed only when clinically appropriate after medical review. We do not claim compounded tirzepatide or compounded semaglutide as FDA-approved, generic, or identical to Zepbound®, Mounjaro®, Wegovy®, or Ozempic®.
Physician-Led GLP-1 Care in Utah
Potere Health MD provides physician-led GLP-1 weight loss care for eligible patients in Utah, with in-person options in St. George, Cedar City, and Salt Lake City/Holladay, plus telehealth visits when appropriate.
Whether you are comparing GLP-1 treatment options or already have medication questions, we can help review dosing, side effects, pricing, medication quality, and long-term weight maintenance.
Frequently Asked Questions About COAs and GLP-1 Medication
A Certificate of Analysis shows testing information for a specific medication lot. Depending on the document, it may include the medication name, concentration, lot number, assay or potency result, date of analysis, and pass/fail status.
No. A COA does not mean compounded tirzepatide is FDA-approved. A COA is lot-specific testing documentation, not FDA approval.
Lot-specific testing helps connect quality documentation to a specific batch of medication. This can give patients more transparency about the medication lot they receive.
The lot number is usually printed on the medication label. Look near the medication name, concentration, pharmacy information, or beyond-use date.
Potere Health MD regularly updates COAs and keeps the most current semaglutide and tirzepatide batches visible. If your lot number is not listed, the COA may not have been posted yet or may have rotated off the page as newer batches were added. Contact our office if you need assistance reviewing your vial label, lot number, concentration, or dosing instructions.
The 90%–110% assay range means the tested medication strength should fall within 90% to 110% of the labeled amount. This is a common pharmaceutical standard used for FDA-regulated finished medications. A result within this range means the lot passed the listed potency specification.